All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The PsOPsA Hub
Brought to you by Scientific Education Support

The PsOPsA Hub is an independent medical education platform. This activity is supported by an educational grant from Lilly. Funders are allowed no direct influence on our content.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ACR Convergence 2022

Share:

Nov 12, 2022

X post image

9 Jan 2023

#ACR22 | Phillip Mease discussed phase II data of deucravacitinib for #psoriaticarthritis. From baseline to Week 52, the mean DASPA score reduced from high to low.
Read more: https://t.co/c1rrdAx2yX

View on 

X post image

15 Nov 2022

We hope you enjoyed following our live updates and congress coverage.

We covered #ACR22 from Philadelphia, Pennsylvania, as well as virtually.

Keep an eye on our socials for post-congress key points and insights!

#psoriasis #lupus #medicalcongress #rheumatology

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | @RADoctor discussed non-adherence in RA, AxSpa, #psoriaticarthritis & #psoriasis. ~24-35% newly prescribed medications were not filled within 6mo, & tsDMARDs were less likely to be filled at 100+ days.

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | Christopher T. Ritchlin discussed the phase III BE OPTIMAL study of bimekizumab in pts with active #psoriaticarthritis. ~90% of patients completed the study up to week 52, with low discontinuation due to TEAEs.

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | Andrea Rubbert-Roth presented a poster about malignancy rates in pts with RA, PsA, and AS from the SELECT clinical trials of upadacitinib vs ADA and MTX. In #psoriaticarthritis pts treated with UPA, age was found to be a risk factor for malignancy.

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | @DrLauraCoates summarised the BE ACTIVE paper on bimekizumab for #psoriaticarthritis in the A&R & ARD Editors Picks 2022 Session. Most common TEAEs were nasopharyngitis, upper RTI & candida. At 152 wks (NRI): ACR50=52.9%, MDA=51.5% & PASI100=57.7%

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | Andreas Ramming discussed the drivers of organ and joint damage in #psoriaticarthritis. Fibroblast activation protein imaging (FAPi) PET/CT scanning can be used in pts with PsA to distinguish between inflammation and fibrotic disease activity

View on 

X post image

14 Nov 2022

The Psoriasis Hub will be covering the following sessions today:

▪️ Safety & Efficacy of Bimekizumab in Patients with Active #psoriaticarthritis
▪️ Malignancy in Upadacitinib treated pts
▪️ And more!

Stay tuned for updates throughout the day.
#ACR22 #medicalcongress #psoriasis

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | @KohmMichaela discussed difference in responses in female vs male pts with #psoriaticarthritis who were treated with UST monotherapy vs UST+MTX. Regardless of treatment, female pts showed decreased ACR response, compared to males.

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | @AlexisOgdie discussed the impact on PsA disease control in pts who switched to non-TNFi biologic versus pts who cycled to a 2nd line TNFi, after discontinuation of a 1st line TNFi. More switchers achieved improvements in BSA and enthesitis, compared to cyclers.

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | @JosephMerolaMD discussed week 16 results from a phase III study of bimekizumab in pts with active #psoriaticarthritis and inadequate response to TNF inhibitors. All primary and secondary endpoints were met at week 16, with no new safety signals observed.

View on 

X post image

14 Nov 2022

CONGRESS #ACR22 | Philip Mease presented the 52 week results from a phase II trial of deucravacitinib in pts with active #psoriaticarthritis. Key efficacy measures were maintained up to 52 weeks, with no new safety signals observed. #psoriasis

View on 

X post image

13 Nov 2022

The Psoriasis Hub will be covering the following sessions today:

▪️ Safety and Efficacy of Deucravacitinib
▪️ The Impact of Second-Line Therapeutic on Disease Control in Patients with PsA
▪️ And more!

Stay tuned for updates throughout the day.
#ACR22 #medicalcongress #psoriasis

View on 

X post image

12 Nov 2022

#ACR22 https://t.co/AiON1T3VDT

View on 

X post image

12 Nov 2022

CONGRESS #ACR22 | @RADoctor presents on how guselkumab treatment for #psoriaticarthritis impacts work productivity and daily activity. Improvements seen at Week 24 were maintained & increased at 2 years. Employment increased by >20% in patients who had been unemployed at baseline

View on 

X post image

12 Nov 2022

CONGRESS #ACR22 | Frank Behrens presented a poster of the 16 week results of izokibep in patients with PsA from a phase II trial. All PROs showed improvement at 16 weeks.

View on 

X post image

12 Nov 2022

CONGRESS #ACR22 | @AlexisOgdie presented a poster about PEST screening in #psoriasis patients from the Psoriasis and Beyond study. PEST positive patients were found to have more comorbidities than PEST negative patients.

View on 

X post image

12 Nov 2022

CONGRESS #ACR22 | @DrLauraCoates presented a poster on efficacy of upadacitinib and adalimumab on RAPID3 scores. Patients treated with upadacitinib had a greater improvement in RAPID3 scores, compared to patients treated with adalimumab.

View on 

X post image

12 Nov 2022

The Psoriasis Hub will be bringing you live updates as we continue our in-person and online coverage of #ACR22.

Sessions covered today:
▪️ Upadacitinib vs Adalimumab in pts with PsA
▪️ Characteristics Associated with a Positive PEST Screening
▪️ And more!

#medicalcongress

View on 

X post image

10 Nov 2022

#ACR22 starts today!

The @psoriasis_hub is covering ACR virtually and in person.

Keep an eye on our Twitter page for live updates, key insights, and interview coverage.

#medicalcongress #rheumatology #psoriasis #lupus

View on 

X post image

9 Nov 2022

The @psoriasis_hub is covering the ACR Convergence 2022!

📅 Date: Nov 10–14
📍 Location: Hybrid

Keep an eye on our socials for live coverage from our virtual and in-person attendance in Philadelphia, Pennsylvania.

#ACR22 #medicalcongress #rheumatology #psoriasis #lupus

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ACR 2022American College of Rheumatology Convergence

Newsletter

Subscribe to get the best content delivered to your inbox